Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine

Journal of Nuclear Medicine

Volumn 50, Issue 5, 2009, Pages 781-789

  Ahlgren, Sara ^a   Wållberg, Helena ^b   Tran, Thuy A ^a   Widström, Charles ^c   Hjertman, Magnus ^b   Abrahmsén, Lars ^b   Berndorff, Dietmar ^d   Dinkelborg, Ludger M ^d   Cyr, John E ^d   Feldwisch, Joachim ^a,b   Orlova, Anna ^a,b   Tolmachev, Vladimir ^a,b,e  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d BAYER PHARMA AG   (Germany)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecule; C terminal cysteine; HER2; Imaging; Technetium

Indexed keywords

CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2:2395 CYSTEINE TC 99M; EPIDERMAL GROWTH FACTOR RECEPTOR 2:342 CYSTEINE TC 99M; POLYHISTIDINE TAG; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; ISOTOPE LABELING; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; RADIOACTIVITY; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CYSTEINE; DRUG DELIVERY SYSTEMS; FEMALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; MOLECULAR PROBE TECHNIQUES; ORGAN SPECIFICITY; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 66149150263     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.056929     Document Type: Article

References (36)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
3. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11(suppl 1):4-12.
4. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268-5272.
5. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
6. Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281-293.
7. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032-3038.
8. Behr TM, Béhé M, Wörmann B. Trastuzumab and breast cancer. N Engl J Med. 2001;345:995-996.
9. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282. (Pubitemid 46630657)
10. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14:2999-3019.
11. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsén L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther. 2007;7:555-568.
12. Orlova A, Magnusson M, Eriksson T, et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res. 2006;66:4339-4348.
13. Mume E, Orlova A, Nilsson F, et al. Evaluation of (4-hydroxyphenyl) ethylmaleimide for site-specific radiobromination of anti-HER2 Affibody. Bioconjug Chem. 2005;16:1547-1555. (Pubitemid 41683137)
14. HER2:342, an Affibody ligand conjugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging. 2007;51:314-323.
15. HER2:342, a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med. 2007;20:397-404.
16. HER2:342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006;47:846-853.
17. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic Affibody molecules: a novel class of affinity ligands for molecular imaging of HER2 expressing malignant tumors. Cancer Res. 2007;67:2178-2189.
18. Feldwisch J, Orlova A, Tolmachev V, Baum R. Clinical and pre-clinical application of HER2-specific Affibody molecules for diagnosis of recurrent HER2 positive breast cancer by SPECT or PET/CT [abstract]. Mol Imaging. 2006;5(suppl):215.
19. 99mTc-chelating mercaptoacetyl-glycylglycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging. 2007;34:722-733.
20. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging. 2007;34:1843-1853.
21. HER2:342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem. 2007;18:1956-1964.
22. Orlova A, Nilsson FY, Wikman M, et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 Affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med. 2006;47:512-519. (Pubitemid 46768494)
23. Liberatore M, Neri D, Neri G, et al. Efficient one-step direct labelling of recombinant antibodies with technetium-99m. Eur J Nucl Med. 1995;22:1326-1329.
24. George AJ, Jamar F, Tai MS, et al. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci USA. 1995;92:8358-8362.
25. 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med. 2006;47:1707-1716.
26. 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem. 2007;18:549-558.
27. 99TcO] apcitide: a technetium labeled peptide. Inorg Chem. 2004;43:2867-2875.
28. 2 core. Inorg Chem. 1981;20:1629-1632.
29. Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem. 2008;19:235-243.
30. Orlova A, Feldwisch J, Abrahmsén L, Tolmachev V. Update: Affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm. 2007;22:573-584. (Pubitemid 350058993)
31. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
32. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004;3:379-398.
33. 89Zr-trastuzumab for clinical HER2 immunoPET imaging [abstract]. J Clin Oncol. 2007;25(suppl):3508.
34. Orlova A, Wållberg H, Tolmachev V. Optimisation of specific radioactivity of Affibody molecule enables in vivo discrimination between high and low HER2 expression [abstract]. Eur J Nucl Med Mol Imaging. 2008;35(suppl 2):S187.
35. 99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun. 2005;26:427-432.
36. Yang D, Kuan CT, Payne J, et al. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Clin Cancer Res. 1998;4:993-1004.